99 related articles for article (PubMed ID: 6181822)
1. [Treatment of leukemias and lymphomas with interferons: I. Trial of myeloma therapy with human beta-interferon].
Misset JL; Mathé G; Gastiaburu J; Goutner A; Dorval T; Gouveia J; Hayat M; Jasmin C; Schwarzenburg L; Machover D; Ribaud P; De Vassal F; Horosezewicz JS
Biomed Pharmacother; 1982 Jan; 36(1):55-9. PubMed ID: 6181822
[TBL] [Abstract][Full Text] [Related]
2. Treatment of lymphoid neoplasias with interferon. I. Human fibroblastic beta-interferon in malignant gammapathies. Phase II trial.
Misset JL; Mathé G; Gastiaburu J; Goutner A; Dorval T; Gouveia J; Hayat M; Jasmin C; Schwarzenberg L; Machover D; Ribaud P; De Vassal F; Horoszewicz JS
Anticancer Res; 1982; 2(1-2):63-6. PubMed ID: 6180675
[TBL] [Abstract][Full Text] [Related]
3. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
4. Treatment of lymphoid neoplasias with interferon. II. Human leucocyte alpha-interferon in chronic lymphatic leukemia (CLL). PHase I-II trial.
Misset JL; Mathé G; Gastiaburu J; Goutner A; Dorval T; Gouveia J; Hayat M; Jasmin C; Schwarzenberg L; Machover D; Ribaud P; De Vassal F
Anticancer Res; 1982; 2(1-2):67-9. PubMed ID: 6180676
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of leukemias and lymphomas by interferons: II. Phase II of the trial treatment of chronic lymphoid leukemia by human interferon alpha+].
Misset JL; Mathé G; Gastiaburu J; Goutner A; Dorval T; Gouveia J; Schwarzenberg L; Machover D; Ribaud P; de Vassal F
Biomed Pharmacother; 1982 Mar; 36(2):112-6. PubMed ID: 7126777
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials referral resource. Multiple myeloma and Waldenström's macroglobulinemia phase III trials.
Cheson BD; Phillips PH
Oncology (Williston Park); 1994 Jul; 8(7):45, 48-50. PubMed ID: 7917838
[No Abstract] [Full Text] [Related]
7. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
9. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and therapy of multiple myeloma: current aspects].
Betticher DC; Cerny T; Fey MF
Schweiz Med Wochenschr; 1995 Mar; 125(11):541-51. PubMed ID: 7899848
[TBL] [Abstract][Full Text] [Related]
11. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
13. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
14. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
[TBL] [Abstract][Full Text] [Related]
15. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
[TBL] [Abstract][Full Text] [Related]
16. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
18. [Interferons. Treatment of malignant hemopathies with interferons].
Guilhot F; Sadoun A; Delwail V
Ann Med Interne (Paris); 1993; 144(8):548-56. PubMed ID: 7513980
[TBL] [Abstract][Full Text] [Related]
19. Interferons in the treatment of multiple myeloma.
Ohno R
Int J Cancer Suppl; 1987; 1():14-20. PubMed ID: 2442112
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
